Status:
UNKNOWN
Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Most Angiotensin receptor blocker's (ARBs) are metabolized by cytochrome P4502C9 (CYP2C9), one of the major isoforms of the cytochrome P450 in human liver microsome. The purpose of this study is to ev...
Detailed Description
Losartan, the first angiotentsin II receptor blocker (ARB), is known to reduce blood pressure (BP). The LIFE study, Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Red...
Eligibility Criteria
Inclusion
- The study will include 30 patients with the 3 most prevalent alleles of CYP2C9 \*1, \*2 and\*3, 10 patients of each group.
Exclusion
- Patients treated with losartan or valsartan prior to their enrollment to the study,
- Patients with BP below 140 systolic or 90 diastolic in an ambulatory 24 hours BP monitoring, acute coronary syndrome during the 6 months previous to the study,
- Renal failure with creatinin levels above 1.5 mg/dL, hyperkalemia (K \> 5 mg/dL),
- Hematologic or solid malignancies or pregnancy.
- Patients will also be excluded from the study if they are known to use one of the drugs inducing or inhibiting the CYP2C9, such as
- rifampicin carbamazepine,
- ethanol,
- phenobarbitone,
- fluconazole,
- amiodarone,
- trimethoprim,
- fluvastatin,
- cimetidine
- chloramphenicol.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00732966
Start Date
September 1 2008
Last Update
August 12 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.